Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with doses escalating from 50 to 150 mg daily for 12 weeks. Response kinetics suggested that more prolonged administration of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Winkler, Thomas, Fan, Xing, Cooper, James, Desmond, Ronan, Young, David J., Townsley, Danielle M., Scheinberg, Phillip, Grasmeder, Sophia, Larochelle, Andre, Desierto, Marie, Valdez, Janet, Lotter, Jennifer, Wu, Colin, Shalhoub, Ruba N., Calvo, Katherine R., Young, Neal S., Dunbar, Cynthia E.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2019
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6566590/
https://ncbi.nlm.nih.gov/pubmed/30992268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000478
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky